Press Release May 23, 2019

AlloVir Joins ElevateBio’s Portfolio of Highly Innovative Cell and Gene Therapy Companies, Raises $120 Million in Series B Financing

The Life Sciences team advised AlloVir, formerly known as ViraCyte, in its joining ElevateBio’s growing portfolio of highly innovative companies. The team also advised AlloVir in its $120 million Series B financing led by Fidelity Management and Research Company, and joined by Gilead Sciences, F2 Ventures, Redmile Group, Invus, EcoR1 Capital, Samsara BioCapital and Leerink Partners Co-investment Fund, LLC.

AlloVir, a late-clinical stage allogeneic cell therapy company, is built on an innovative technology platform developed by researchers at Baylor College of Medicine’s Center for Cell and Gene Therapy. The company’s platform and manufacturing process enables the potential for the treatment and/or prevention of multiple devastating viruses with each single allogeneic cell therapy targeting multiple viruses at once. AlloVir’s scientific founders are working with ElevateBio to continue to build the company and accelerate development of its highly innovative pipeline to transform the lives of patients suffering from virus-associated diseases.

The Goodwin team was led by partners Danielle Lauzon and Mitchell Bloom, and associates Patricia Mets, Gabriela Morales-Rivera, Kimberly Maruncic and Katherine Hand, with assistance from partner Janet Andolina. The core team also advised ElevateBio in it’s recent $150 million Series A financing.

For additional details, please read the press release and articles in FierceBiotech, Xconomy and Crunchbase.